Scholarlink

Background <p>Grade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic significance in GG1 disease remains incompletely defined.</p> Methods <p>Retrospective cohort of 40 patients with GG1 and pT3a disease on RP (2000–2022), confirmed on central pathologic re-review.</p> Results <p>Four patients developed biochemical recurrence (BCR); the cumulative incidence of BCR was 3.2% at 5 years and 10.3% at 15 years. No patient developed metastatic disease or prostate cancer–specific mortality.</p> Conclusions <p>GG1 pT3a prostate cancer demonstrates excellent long-term outcomes. Adverse histologic features, not pathological stage alone, drive clinically meaningful risk. Late, stable PSA detectability alone does not signify meaningful recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Mohamad Watfa,
  • Kristina Dortche,
  • Gagan Fervaha,
  • Salim K. Younis,
  • Abdulrahman Al-Bayati,
  • Betty Wang,
  • Rui M. Bernardino,
  • Jesse K. McKenney,
  • Samuel Haywood,
  • Ruben Olivares,
  • Riccardo Autorino,
  • Jihad Kaouk,
  • Christopher J. Weight,
  • Zeyad R. Schwen,
  • Jane K. Nguyen

摘要

Background

Grade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic significance in GG1 disease remains incompletely defined.

Methods

Retrospective cohort of 40 patients with GG1 and pT3a disease on RP (2000–2022), confirmed on central pathologic re-review.

Results

Four patients developed biochemical recurrence (BCR); the cumulative incidence of BCR was 3.2% at 5 years and 10.3% at 15 years. No patient developed metastatic disease or prostate cancer–specific mortality.

Conclusions

GG1 pT3a prostate cancer demonstrates excellent long-term outcomes. Adverse histologic features, not pathological stage alone, drive clinically meaningful risk. Late, stable PSA detectability alone does not signify meaningful recurrence.